Myriad Genetics unveils Precise MRD test for advanced molecular disease detection

Myriad Genetics unveils Precise MRD test for advanced molecular disease detection
Myriad Genetics unveils MRD test

Myriad Genetics will host an Industry Expert Theater at ASCO26 tomorrow at 9:30 AM to present its Precise MRD test for ultra sensitive detection of molecular residual disease.

The session, led by Dale Muzzey, PhD, Chief Scientific Officer of Myriad Genetics, will detail the technical aspects of the assay and showcase the latest advancements in molecular diagnostics. This presentation is expected to highlight new opportunities for precision oncology and clinical research.

Myriad recently introduced the Prolaris plus AI test to advance precision in prostate cancer risk assessment. The company stated that the Prolaris plus AI Test unites molecular scores with digital pathology powered by artificial intelligence. These initiatives reflect the company's continued focus on molecular diagnostics and clinical innovation.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.